The run up to the 2026/27 flu season has been anything but routine. What should have been a predictable annual cycle of ordering, scheduling, and delivering vaccinations has instead become a lesson in supply chain fragility, shifting delivery models, and the growing tension between national ambition and local operational reality.

For practice managers, the question is simple: how do we run a safe, financially viable flu programme when the ground keeps moving beneath us?

This blog summarises the key developments since mid‑July and what they mean for primary care teams preparing for winter.

A Sudden Shock: The Sanofi Batch Failure

On 20 August, practices across England were informed that deliveries of the Sanofi Trivalent Influenza Vaccine (IIVr) were cancelled nationwide. A manufacturing failure, combined with late identification of an unexpected B‑strain candidate, resulted in the loss of around 2 million doses.

For practices that had ordered IIVr, the message was stark: You will receive no stock at all from this supplier.

The timing could hardly be worse. Many practices had already scheduled clinics, booked venues, and begun patient communications. Overnight, plans had to be revisited, re‑sequenced, or paused entirely.

Is This a National Shortage? The Nuanced Answer

NHS England has been clear that a national shortage is not expected. Alternative suppliers — particularly CSL Seqirus — report sufficient stock to meet overall demand.

But this reassurance comes with caveats:

• Replacement stock from Sanofi (IIV‑HD) may not arrive until November.
• Delivery weeks remain unconfirmed.
• Practices must avoid ordering non‑reimbursable vaccines, which could create financial exposure.
• Local shortages and clinic disruption are highly likely, even if national totals balance out.

In other words: the system may have enough vaccine, but not necessarily in the right place at the right time.

Financial Viability Under Pressure in the NHS Flu Programme 2026

The supply disruption lands in a year when many practices already question whether the flu programme is economically sustainable.

The Item of Service fee remains £10.06, unchanged for many years, despite rising staffing costs, venue hire, consumables, and the administrative burden of running large clinics. Delayed stock, rescheduled clinics, and potential drops in uptake only add to the pressure.

For some practices, the flu programme is becoming a marginal activity — essential for public health, but increasingly difficult to deliver without absorbing losses.

A Changing Delivery Landscape: Pharmacies Step Forward

This season also marks a structural shift in how flu vaccinations are delivered.

From 1 October 2026, community pharmacies can vaccinate:

• 2‑ and 3‑year‑olds
• Children aged 2–17 in clinical risk groups

And from 1 December, pharmacies can vaccinate school‑aged children who missed SAIS clinics.

This expansion is intended to increase access and reduce pressure on general practice — but it also introduces new coordination challenges:

• Ensuring consistent messaging across PCNs, SAIS teams, and pharmacies
• Managing patient expectations when stock availability differs between providers
• Avoiding duplication or gaps in coverage

Pharmacies will also face ordering controls, with LAIV supplied centrally via the Federated Data Platform. This adds another layer of operational complexity across the system.

Ambitious Uptake Targets in a Difficult Year

Despite the disruption, national targets remain unchanged:

• 75% uptake for adults aged 65+
• A renewed push to improve frontline healthcare worker vaccination rates
• Strong encouragement for vaccination among clinical risk groups

Achieving these targets will require clear communication, flexible clinic planning, and close collaboration across local systems — all while navigating uncertain supply.

Practice Manager Flu Planning: What to Focus on Now

1. Reassess clinic plans early: If your practice was relying on Sanofi stock, revisit dates, staffing, and venue bookings now. Avoid committing to large clinics until replacement stock is confirmed.

2. Communicate proactively with patients: Clear, calm messaging will be essential. Patients should understand that delays are due to national supply issues, not local decisions.

3. Coordinate closely with pharmacies and PCN partners: Shared planning can prevent duplication and ensure vulnerable groups are prioritised.

4. Protect financial viability: Avoid ordering non‑reimbursable vaccines and review the cost implications of rescheduling clinics.

5. Prepare for fluctuating demand: As pharmacies vaccinate more children, general practice may see a shift in patient flow — helpful in some areas, challenging in others.

Looking Ahead to Winter 2026/27

This flu season will test the resilience of primary care teams. 

Yet the fundamentals remain the same: deliver safe care, communicate clearly, and work collaboratively across the system.

If the past few years have shown anything, it’s that primary care can adapt quickly when needed. This winter will require exactly that — flexibility, realism, and a shared commitment to protecting patients despite the challenges.